

# Romain Cohen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2204188/publications.pdf>

Version: 2024-02-01

87  
papers

2,460  
citations

257101

24  
h-index

315357

38  
g-index

103  
all docs

103  
docs citations

103  
times ranked

3995  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the TGF $\beta$ 2 pathway for cancer therapy. , 2015, 147, 22-31.		513
2	Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncology, 2019, 5, 551.	3.4	178
3	Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget, 2015, 6, 16832-16847.	0.8	100
4	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. Journal of the National Cancer Institute, 2018, 110, 68-77.	3.0	89
5	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology, 2021, 39, 642-651.	0.8	84
6	Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. European Journal of Cancer, 2017, 86, 266-274.	1.3	65
7	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. Clinical Cancer Research, 2019, 25, 2109-2115.	3.2	65
8	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Targeted Oncology, 2020, 15, 11-24.	1.7	65
9	Immunotherapy and patients treated for cancer with microsatellite instability. Bulletin Du Cancer, 2017, 104, 42-51.	0.6	64
10	MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. Bulletin Du Cancer, 2019, 106, 119-128.	0.6	61
11	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. International Journal of Cancer, 2020, 147, 285-296.	2.3	56
12	Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2021, 113, 208-211.	3.0	56
13	BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. Current Treatment Options in Oncology, 2017, 18, 9.	1.3	51
14	Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study. Bulletin Du Cancer, 2015, 102, 324-331.	0.6	47
15	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
16	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. , 2020, 8, e001499.		43
17	Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer. ESMO Open, 2021, 6, 100120.	2.0	42
18	Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). Journal of Clinical Oncology, 2020, 38, 1702-1710.	0.8	40

#	ARTICLE	IF	CITATIONS
19	Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 9-16.	1.3	40
20	Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)†. <i>Annals of Oncology</i> , 2021, 32, 1267-1275.	0.6	39
21	Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 244-244.	0.8	39
22	Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. <i>Gastroenterology</i> , 2021, 161, 814-826.e7.	0.6	36
23	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. <i>European Journal of Cancer</i> , 2021, 143, 55-63.	1.3	32
24	Molecular Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2350.	1.7	30
25	Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. <i>Cancers</i> , 2021, 13, 1149.	1.7	30
26	Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3006-3006.	0.8	28
27	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	7.7	28
28	A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification. <i>Cancer Treatment Reviews</i> , 2022, 103, 102325.	3.4	26
29	Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 824-833.	0.4	25
30	BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , 2019, 11, 998.	1.7	22
31	Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. <i>Bulletin Du Cancer</i> , 2019, 106, 137-142.	0.6	22
32	Characteristics of <i>BRAF</i> V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	1.9	20
33	Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 233-241.	1.8	18
34	Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy. <i>Clinical Rheumatology</i> , 2019, 38, 601-602.	1.0	17
35	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	3.0	17
36	Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1227-1238.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	1.3	15
38	Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer. , 2021, 9, e001903.		15
39	Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). <i>European Journal of Cancer</i> , 2019, 107, 46-52.	1.3	14
40	Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 172, 171-181.	1.3	14
41	New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. <i>Current Oncology Reports</i> , 2016, 18, 18.	1.8	12
42	Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours. <i>Neuroendocrinology</i> , 2020, 110, 404-412.	1.2	12
43	Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. <i>Cancers</i> , 2020, 12, 1990.	1.7	12
44	A comprehensive overview of promising biomarkers in stage II colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 88, 102059.	3.4	12
45	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
46	One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 13-13.	0.8	12
47	Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. <i>Cancer Medicine</i> , 2019, 8, 5079-5088.	1.3	11
48	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 406.	1.7	11
49	Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study. <i>World Journal of Surgical Oncology</i> , 2022, 20, 131.	0.8	10
50	RECIST and Choi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. <i>Cancer Imaging</i> , 2019, 19, 85.	1.2	9
51	A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. <i>Annals of Oncology</i> , 2017, 28, v180.	0.6	8
52	Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E23-E27.	0.6	7
53	Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy. <i>Annals of Oncology</i> , 2018, 29, viii179-viii180.	0.6	6
54	Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCO-0307 trial. <i>Gastric Cancer</i> , 2019, 22, 577-586.	2.7	6

#	ARTICLE	IF	CITATIONS
55	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	3.0	5
56	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	3.0	5
57	Immune microenvironment in patients with mismatch repair proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. <i>Molecular Oncology</i> , 2022, 16, 2260-2273.	2.1	5
58	Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. <i>Clinical Colorectal Cancer</i> , 2021, 20, 79-83.e4.	1.0	4
59	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101681.	0.7	4
60	Food insecurity in French patients with diabetes. <i>Diabetes and Metabolism</i> , 2014, 40, 314-316.	1.4	3
61	Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer – “Beyond the Misdiagnosis” In Reply. <i>JAMA Oncology</i> , 2019, 5, 741.	3.4	3
62	Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. <i>Clinical Trials</i> , 2021, 18, 51-60.	0.7	3
63	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	3
64	Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 7551-7561.	1.0	3
65	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.4	3
66	Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study. <i>European Journal of Cancer</i> , 2022, 168, 99-107.	1.3	3
67	Is it permissible to undertake surgery for adrenal metastases of esophageal adenocarcinomas?. <i>Journal of Visceral Surgery</i> , 2019, 156, 275.	0.4	2
68	Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e15537-e15537.	0.8	2
69	Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 188-188.	0.8	2
70	Immune checkpoint inhibitors in colorectal cancer: dream and reality. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 4-6.	3.7	2
71	Immune checkpoint inhibitors for patients with colorectal cancer: mismatch repair deficiency and perspectives. <i>Colorectal Cancer</i> , 2017, 6, 23-31.	0.8	1
72	46P [18F]2-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18FDG-PET/CT) in patients treated with immune checkpoint inhibitors (ICI) for microsatellite instability-high metastatic colorectal cancer (MSI mCRC). <i>Annals of Oncology</i> , 2020, 31, S1434.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Parameters associated with outcomes in pretreated MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Subgroup analysis of a prospective cohort.. Journal of Clinical Oncology, 2021, 39, 3580-3580.	0.8	1
74	Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).. Journal of Clinical Oncology, 2019, 37, 3121-3121.	0.8	1
75	RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study.. Journal of Clinical Oncology, 2020, 38, 101-101.	0.8	1
76	Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma. Digestive and Liver Disease, 2023, 55, 276-282.	0.4	1
77	Reply to the Letter by S. Sorscher Regarding "Implications of BRAF Mutations in dMMR Colorectal Cancers": Current Treatment Options in Oncology, 2017, 18, 63.	1.3	0
78	Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma. Case Reports in Gastrointestinal Medicine, 2019, 2019, 1-3.	0.2	0
79	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. Journal of Clinical Oncology, 2021, 39, 10-10.	0.8	0
80	Identification of baseline parameters associated with the inter-individual variability in cytidine deaminase serum activity, a key enzyme in the metabolism of pyrimidine analogue.. Journal of Clinical Oncology, 2016, 34, e14096-e14096.	0.8	0
81	Clinical and molecular characterization of patients with metastatic colorectal cancer harbouring DNA mismatch repair deficiency.. Journal of Clinical Oncology, 2017, 35, 3563-3563.	0.8	0
82	Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST).. Journal of Clinical Oncology, 2018, 36, 4035-4035.	0.8	0
83	Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).. Journal of Clinical Oncology, 2019, 37, e15046-e15046.	0.8	0
84	Prognostic value of tumor deposits for disease free survival in patients with stage III colon cancer: A post hoc analysis of IDEA France phase III trial (PRODIGE-GERCOR).. Journal of Clinical Oncology, 2019, 37, 3519-3519.	0.8	0
85	Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	0
86	Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.. Journal of Clinical Oncology, 2022, 40, 3606-3606.	0.8	0
87	First-line (L1) therapy targeting EGFR in lung metastases (mets) of colorectal cancer (mCRC): An ARCAD pooled analysis.. Journal of Clinical Oncology, 2022, 40, 3578-3578.	0.8	0